Percutaneous Ventricular Septal Defect Closure in Patients Under 1 Year of Age

Nazmi Narin1, Ozge Pamukcu2, Aydin Tuncay3

  • 1Division of Pediatric Cardiology, Erciyes University School of Medicine, 38039, Kayseri, Turkey.

Pediatric Cardiology
|March 16, 2018
PubMed

Insights

Percutaneous closure of ventricular septal defects (VSDs) in infants under one year is a viable, less invasive alternative to surgery. This approach offers similar risks but may be preferred for early infancy VSD treatment.

Area of Science:

  • Pediatric Cardiology
  • Interventional Cardiology
  • Congenital Heart Disease

Background:

  • Untreated ventricular septal defects (VSDs) are a leading cause of congestive heart failure in infants.
  • Surgical VSD closure in infants is complicated by pulmonary congestion, respiratory infections, and poor nutritional status.
  • Infants with VSD often experience impaired growth.

Purpose of the Study:

  • To evaluate the safety and efficacy of percutaneous VSD closure in patients younger than one year.
  • To share institutional experience with this minimally invasive technique.

Main Methods:

  • Retrospective study of 12 patients under one year with hemodynamically significant VSDs (diameter ≤ 6 mm).
  • VSD closure performed using Amplatzer Duct Occluder II (ADO II) or ADO II-additional size devices.
  • Follow-up duration was a median of 8.5 months.

Main Results:

  • The mean VSD diameter was approximately 4.7 mm.
  • No device-related aortic regurgitation was observed.
  • One patient developed complete atrioventricular block 6 months post-procedure, requiring a pacemaker.

Conclusions:

  • Percutaneous VSD closure is a challenging but feasible option for infants.
  • While risks are comparable to surgery, percutaneous closure is less invasive.
  • This technique may be the preferred alternative for VSD closure in early infancy.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
241
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
713
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
265
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
227
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
259
Lumber Defects01:23

Lumber Defects

Lumber defects, which can affect both the appearance and structural integrity of wood, include a variety of growth and manufacturing flaws. Growth defects such as knots and knotholes occur where branches were once attached to the tree trunk, with knotholes forming when these knots fall out. Other natural defects include decay and insect damage, which compromise the wood's strength and durability.
Shakes are minor fractures that run along or across the wood's annual rings, while wane is...
562